Biophytis Announces New Non-Clinical Data Further Supporting Its Mission to Pioneer the Restoration of Mobility in Patients with Obesity
Biophytis has revealed new preclinical data for its investigational drug BIO101 at the 15th International Conference on Frailty and Sarcopenia Research. The study shows that BIO101, when combined with GLP-1, significantly improved mobility and grip strength in diet-induced obese mice over a four-week treatment period.
The research demonstrates that the drug combination compensates for muscle contractility alterations caused by GLP-1 in isolated muscle tests. Previous early-phase clinical trials, including the SARA-INT (Phase 2) study on sarcopenic obesity and Quinolia (Phase 1-2) study, showed improved muscle strength and mobility in BIO101-treated obese patients compared to placebo groups.
This development addresses a significant health concern, as 96% of obesity patients report muscle strength decline. With obesity affecting nearly one billion people globally, Biophytis aims to advance BIO101's development in combination with GLP-1 through their Phase 2 OBA clinical trial.
Biophytis ha rivelato nuovi dati preclinici per il suo farmaco in fase di sperimentazione BIO101 durante la 15ª Conferenza Internazionale sulla Ricerca sulla Fragilità e Sarcopenia. Lo studio mostra che BIO101, quando combinato con GLP-1, ha migliorato significativamente la mobilità e la forza di presa nei topi obesi indotti da dieta nel corso di un periodo di trattamento di quattro settimane.
La ricerca dimostra che la combinazione di farmaci compensa le alterazioni della contrattività muscolare causate da GLP-1 in test muscolari isolati. I precedenti studi clinici in fase iniziale, incluso lo studio SARA-INT (Fase 2) sull'obesità sarcopenica e lo studio Quinolia (Fase 1-2), hanno mostrato un miglioramento della forza muscolare e della mobilità nei pazienti obesi trattati con BIO101 rispetto ai gruppi placebo.
Questo sviluppo affronta una significativa preoccupazione sanitaria, poiché il 96% dei pazienti obesi riporta un declino della forza muscolare. Con l'obesità che colpisce quasi un miliardo di persone a livello globale, Biophytis mira a portare avanti lo sviluppo di BIO101 in combinazione con GLP-1 attraverso il loro trial clinico di Fase 2 OBA.
Biophytis ha revelado nuevos datos preclínicos para su medicamento en investigación BIO101 en la 15ª Conferencia Internacional sobre Investigación de Fragilidad y Sarcopenia. El estudio muestra que BIO101, cuando se combina con GLP-1, mejoró significativamente la movilidad y la fuerza de agarre en ratones obesos inducidos por dieta durante un período de tratamiento de cuatro semanas.
La investigación demuestra que la combinación de medicamentos compensa las alteraciones de la contractilidad muscular causadas por GLP-1 en pruebas musculares aisladas. Ensayos clínicos anteriores en fases iniciales, incluido el estudio SARA-INT (Fase 2) sobre obesidad sarcopénica y el estudio Quinolia (Fase 1-2), mostraron una mejora en la fuerza muscular y la movilidad en pacientes obesos tratados con BIO101 en comparación con los grupos placebo.
Este desarrollo aborda una preocupación de salud significativa, ya que el 96% de los pacientes con obesidad reporta un declive en la fuerza muscular. Con la obesidad afectando a casi mil millones de personas en todo el mundo, Biophytis busca avanzar en el desarrollo de BIO101 en combinación con GLP-1 a través de su ensayo clínico de Fase 2 OBA.
Biophytis는 제15회 국제 노쇠 및 근감소증 연구 회의에서 실험 약물 BIO101에 대한 새로운 전임상 데이터를 공개했습니다. 연구에 따르면, BIO101은 GLP-1과 결합했을 때, 4주 치료 기간 동안 식이 유도 비만 쥐의 이동성과 그립 강도를 유의미하게 개선했습니다.
이 연구는 약물 조합이 분리된 근육 테스트에서 GLP-1에 의해 발생한 근육 수축성 변화에 보상한다는 것을 보여줍니다. 이전 초기 단계의 임상 시험, 즉 근감소증 비만에 대한 SARA-INT(2상) 연구와 Quinolia(1-2상) 연구는 BIO101 치료를 받은 비만 환자들이 위약 그룹에 비해 근력과 이동성이 개선되었음을 보여주었습니다.
이 발전은 96%의 비만 환자가 근력 감소를 보고하는 중요한 건강 문제를 다룹니다. 비만이 전 세계적으로 거의 10억 명에게 영향을 미치고 있는 상황에서, Biophytis는 2상 OBA 임상 시험을 통해 GLP-1과의 조합으로 BIO101의 개발을 진행할 계획입니다.
Biophytis a révélé de nouvelles données précliniques pour son médicament expérimental BIO101 lors de la 15e Conférence Internationale sur la Recherche sur la Fragilité et la Sarcopénie. L'étude montre que BIO101, lorsqu'il est combiné avec le GLP-1, améliore de manière significative la mobilité et la force de préhension chez des souris obèses induites par le régime alimentaire sur une période de traitement de quatre semaines.
La recherche démontre que la combinaison de médicaments compense les altérations de la contractilité musculaire causées par le GLP-1 dans des tests musculaires isolés. Des essais cliniques précoces antérieurs, y compris l'étude SARA-INT (Phase 2) sur l'obésité sarcopénique et l'étude Quinolia (Phase 1-2), ont montré une amélioration de la force musculaire et de la mobilité chez les patients obèses traités avec BIO101 par rapport aux groupes placebo.
Ce développement répond à une préoccupation de santé majeure, car 96% des patients obèses rapportent une diminution de la force musculaire. Avec l'obésité touchant près d'un milliard de personnes dans le monde, Biophytis vise à faire avancer le développement de BIO101 en combinaison avec le GLP-1 à travers leur essai clinique de Phase 2 OBA.
Biophytis hat auf der 15. Internationalen Konferenz zur Forschung über Gebrechlichkeit und Sarkopenie neue präklinische Daten zu seinem experimentellen Medikament BIO101 veröffentlicht. Die Studie zeigt, dass BIO101 in Kombination mit GLP-1 die Mobilität und die Griffkraft bei diätinduzierter Fettleibigkeit bei Mäusen über einen Zeitraum von vier Wochen signifikant verbessert hat.
Die Forschung zeigt, dass die Medikamentenkombination die durch GLP-1 verursachten Veränderungen der Muskelkontraktilität in isolierten Muskeltests ausgleicht. Frühere klinische Studien in frühen Phasen, einschließlich der SARA-INT-Studie (Phase 2) zur sarkopenischen Fettleibigkeit und der Quinolia-Studie (Phase 1-2), zeigten eine Verbesserung der Muskelkraft und Mobilität bei mit BIO101 behandelten fettleibigen Patienten im Vergleich zu Placebo-Gruppen.
Diese Entwicklung spricht ein bedeutendes Gesundheitsproblem an, da 96% der Fettleibigkeitspatienten einen Rückgang der Muskelkraft berichten. Da Fettleibigkeit weltweit fast eine Milliarde Menschen betrifft, strebt Biophytis an, die Entwicklung von BIO101 in Kombination mit GLP-1 durch ihre Phase-2-OBA-Studie voranzutreiben.
- Successful preclinical results showing BIO101 + GLP-1 improved mobility and muscle strength
- Positive early-phase clinical trial results from SARA-INT and Quinolia studies
- Addresses large market opportunity with nearly 1 billion people affected by obesity
- Product still in early development phases
- Requires combination with GLP-1 to show effectiveness
- No current therapy exists for muscle strength restoration in obesity
96% of patients with obesity report experiencing muscle strength impairment, affecting their mobility- New preclinical study results: The combination of BIO101 and GLP-1 induced muscle strength and mobility restoration in animal model
Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - March 24, 2025) - Biophytis SA (FP: ALBPS) ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in developing treatments for age-related diseases, announces new preclinical results for its investigational drug BIO101. These results were presented for the first time last week at the 15th International Conference on Frailty and Sarcopenia Research in Toulouse.
Key findings on BIO101 in obesity include:
In this newly reported preclinical study BIO101, in combination with GLP-1, protected muscle strength and mobility in an animal model: In this preclinical study conducted on diet-induced obese mice, four weeks combination treatment of BIO101 with a GLP-1 receptor agonist significantly improved animal mobility (endurance) and grip strength when compared to untreated groups. Notably, the combination of drugs compensates for muscle contractility alterations induced by GLP-1 in a twitch test performed on an isolated muscle.
BIO101 showed beneficial effects on muscle strength and mobility in humans in previous early-phase clinical trials: Furthermore, in the SARA-INT (Phase 2) study on sarcopenic obesity and Quinolia (Phase 1-2) study on obesity, the BIO101-treated obese patient cohorts were observed to have improved muscle strength and mobility compared to placebo cohorts.
Addressing a Global Health Crisis
Obesity affects nearly one billion people worldwide and is linked to severe comorbidities, specifically including that
Stanislas Veillet, CEO of Biophytis, stated: "Despite the progress made with the development of GLP-1 treatments for obesity, no therapy currently exists to restore muscle strength and mobility in patients with obesity. Biophytis is pioneering research to address this critical unmet medical need. We are eager to advance the development of BIO101 in combination with GLP-1 within our Phase 2 OBA clinical trial."
The full presentation is available on our website.
About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity, Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company's ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com.
Disclaimer
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face" section from the Company's 2023 Financial Report available on BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether because of new information or otherwise, except as required by law.
Biophytis Contacts
Investor Relations
Investors@biophytis.com
US Investors
Pascal Nigen - Alpha Bronze
pnigen@alphabronzellc.com
Media contacts
Antoine Denry: antoine.denry@taddeo.fr - +33 6 18 07 83 27
Inès de Mandiargues: ines.demandiargues@taddeo.fr - +33 6 16 16 51 78
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/245764
FAQ
What are the key findings of Biophytis' new preclinical study for BIO101 (BPTSY)?
How did BIO101 perform in previous clinical trials for obesity treatment?
What percentage of obesity patients experience muscle strength problems?
What is the next development phase for BIO101 in obesity treatment?
